Dutasteride

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Dutasteride

An FDA-approved 5-alpha reductase inhibitor for benign prostatic hyperplasia, used off-label for hair loss.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved.

Dutasteride (Avodart) is a 5-alpha reductase inhibitor approved by the FDA in 2001 for benign prostatic hyperplasia. It blocks both type 1 and type 2 5-alpha reductase enzymes, converting testosterone to DHT more effectively than finasteride. While FDA-approved only for BPH, it is prescribed off-label for male pattern baldness, where it is approved in South Korea (2009) and Japan (2015).

Benefits reported in the imported source

• Benign prostatic hyperplasia in men.

Risks and limits

• Sexual dysfunction
• Decreased libido
• Off-label use for hair loss not FDA-approved in the U.S.
• Pregnancy category X (teratogenic)

Source bottom line: FDA-approved for BPH only; off-label use for hair loss requires physician judgment and is approved in other countries only.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

No study protocol recorded in this snapshot. This does not establish that no study exists.

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Pharmacokinetic context

Historical half-life estimate: 840 hours. FDA label, Avodart: terminal half-life about 5 weeks at steady state with daily dosing (single-dose values range 170-300 h depending on age) Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• DailyMed: dutasteride
• Dutasteride (Avodart) - American Hair Loss Association
• Avodart Regulatory Status Global - HealthRX